Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):326–333. doi: 10.1097/QAI.0b013e31826be75e

Figure 3.

Figure 3

Cumulative proportions of patients starting antiretroviral therapy over time for CD4 count thresholds of 500, 350 and 200 cells/μl based on measurements from the benchmark CD4 count enumeration technology (flow cytometry) as well as from biased and less precise technologies. δ measures the relative change in the standard deviation of short-term variability of CD4 counts about a subject’s latent CD4 count when using a novel CD4 count enumeration technology versus the flow cytometry.